A new study found that most survivors of stage 0 through stage III breast cancer who try to conceive after completing treatment are able to become pregnant and have a live birth.
The research was presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 31-June 4 in Chicago, Illinois.
“This study was designed to address gaps in the literature by reporting on pregnancy and live birth rates among a prospective group of breast cancer patients and survivors who indicated attempting to conceive following their diagnosis of breast cancer. Moreover, the patient population reported on in this study has a median follow-up of over 10 years and includes those with a history of any prior subtype of breast cancer,” said Dr. Kimia Sorouri, MD, MPH, Research Fellow, Dana-Farber Cancer Institute, Boston, Massachusetts.
This study included 1,213 participants who had been diagnosed with stage 0 to III breast cancer at age 40 or younger from 2006 to 2016. The study did not include people with metastatic disease or those who had their uterus or ovaries removed prior to their breast cancer diagnosis. Of the eligible participants, 197 reported attempting pregnancy over a median follow-up of 11 years.
Among the participants who had attempted pregnancy:
Key Findings
“Evolving data continues to demonstrate not only the possibility but safety of pregnancy and live birth after breast cancer treatment. This study indicated a significant number of BC survivors attempting pregnancy achieved live birth, particularly those with financial comfort. All young patients interested in fertility preservation should have equitable access to preserve future fertility options.” – Elizabeth Comen, Breast Oncologist at Memorial Sloan Kettering Cancer Center
Researchers would like to gain a better understanding of disease outcomes, such as disease-free survival and overall survival, associated with pregnancy and live birth for people with breast cancer.
They would also like to perform additional subgroup analyses, including for people with oestrogen receptor-negative disease.
Source: ASCO